ID   HCC1954-LR
DR   cancercelllines; CVCL_LG20
DR   Wikidata; Q54881621
RX   PubMed=24876102;
CC   Population: East Indian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4017; Breast ductal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1259 ! HCC1954
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 05-10-23; Version: 12
RX   PubMed=24876102; DOI=10.1158/0008-5472.CAN-13-2053;
RA   Rani S., Corcoran C., Shiels L., Germano S., Breslin S., Madden S.F.,
RA   McDermott M.S., Browne B.C., O'Donovan N., Crown J., Gogarty M.,
RA   Byrne A.T., O'Driscoll L.;
RT   "Neuromedin U: a candidate biomarker and therapeutic target to predict
RT   and overcome resistance to HER-tyrosine kinase inhibitors.";
RL   Cancer Res. 74:3821-3833(2014).